Xenetic Biosciences Inc./$XBIO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
Ticker
$XBIO
Sector
Primary listing
Employees
2
Headquarters
Website
XBIO Metrics
BasicAdvanced
$4.7M
-
-$2.05
2.39
-
Price and volume
Market cap
$4.7M
Beta
2.39
52-week high
$13.93
52-week low
$1.90
Average daily volume
50K
Financial strength
Current ratio
4.558
Quick ratio
3.707
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-110.40%
Operating margin (TTM)
-115.80%
Revenue per employee (TTM)
$1,430,000
Management effectiveness
Return on assets (TTM)
-31.56%
Return on equity (TTM)
-57.42%
Valuation
Price to revenue (TTM)
1.111
Price to book
0.8
Price to tangible book (TTM)
0.8
Price to free cash flow (TTM)
-1.169
Free cash flow yield (TTM)
-85.56%
Free cash flow per share (TTM)
-1.762
Growth
Revenue change (TTM)
13.30%
Earnings per share change (TTM)
-22.67%
3-year revenue growth (CAGR)
22.57%
3-year earnings per share growth (CAGR)
-25.76%
10-year earnings per share growth (CAGR)
-40.60%
XBIO News
AllArticlesVideos
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
Accesswire·1 week ago
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
Accesswire·4 weeks ago
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xenetic Biosciences Inc. stock?
Xenetic Biosciences Inc. (XBIO) has a market cap of $4.7M as of December 19, 2025.
What is the P/E ratio for Xenetic Biosciences Inc. stock?
The price to earnings (P/E) ratio for Xenetic Biosciences Inc. (XBIO) stock is 0 as of December 19, 2025.
Does Xenetic Biosciences Inc. stock pay dividends?
No, Xenetic Biosciences Inc. (XBIO) stock does not pay dividends to its shareholders as of December 19, 2025.
When is the next Xenetic Biosciences Inc. dividend payment date?
Xenetic Biosciences Inc. (XBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Xenetic Biosciences Inc.?
Xenetic Biosciences Inc. (XBIO) has a beta rating of 2.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.